- 2,99 €
Beschreibung des Verlags
Introduction High-risk human papilloma virus (HPV) is a sexually transmitted infection and necessary cause of cervical cancer. (1) The development of a vaccine that protects against the high-risk HPV-16 and HPV-18 strains, which are responsible for over 70% of cervical cancers, (2) and implementation of a routine HPV vaccination programme promises greater protection against cervical cancer. Cervarix, given in three doses over six months, protects against strains HPV-16 and HPV-18 and was introduced in the UK from 2008 for girls aged 12 to 13 years, following recommendation by the Joint Committee on Vaccination and Immunisation. In Scotland, recommendations resulting from pre-implementation research informed a media campaign. (3) This emphasised the vaccine's role in the 'prevention of cervical cancer', and was the focus of the national and local campaign heralding the introduction of HPV into the childhood schedule and the catch-up campaign for older girls.